Optimization of multivalent bispecific antibodies and immunocytokines with improved in vivo properties

Bioconjugate Chemistry

Volumn 24, Issue 1, 2013, Pages 63-71

  Rossi, Edmund A ^a,b   Chang, Chien Hsing ^a,b   Cardillo, Thomas M ^b   Goldenberg, David M ^a,b,c  

^a IBC Pharmaceuticals Inc ^*  (United States)

^b IMMUNOMEDICS INC   (United States)

^c CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; BIOCHEMISTRY; C (PROGRAMMING LANGUAGE);

BIOSTRUCTURES; IN-VIVO; MODULAR METHODS; MULTIVALENCY; NATURAL INTERACTIONS; OPTIMISATIONS; PROPERTY; SITE-SPECIFIC; SPECIFIC CONJUGATIONS; TECHNOLOGY PLATFORMS;

PHARMACOKINETICS;

ALPHA2B INTERFERON; BISPECIFIC ANTIBODY; CD20 ANTIBODY; CD22 ANTIGEN; CYTOKINE; EPRATUZUMAB; IMMUNOCYTOKINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; UNCLASSIFIED DRUG; VELTUZUMAB;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; COVALENT BOND; DOCK AND LOCK; DRUG BINDING; DRUG CONJUGATION; DRUG HALF LIFE; DRUG STABILITY; EXPERIMENTAL RABBIT; IN VIVO STUDY; LYMPHOMA; MALE; MOUSE; NONHUMAN; PROTEIN BINDING;

RUMEX;

EID: 84872559106     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc300488f     Document Type: Article

References (31)

1. Kontermann, R. E. (2010) Alternative antibody formats Curr. Opin. Mol. Ther. 12, 176-183
2. Kuo, T. T. and Aveson, V. G. (2011) Neonatal Fc receptor and IgG-based therapeutics MAbs 3, 422-430
3. Rossi, E. A., Goldenberg, D. M., and Chang, C. H. (2012) The dock-and-lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures Bioconjugate Chem. 23, 309-323
4. Baillie, G. S., Scott, J. D., and Houslay, M. D. (2005) Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract FEBS Lett. 579, 3264-3270
5. Wong, W. and Scott, J. D. (2004) AKAP signalling complexes: focal points in space and time Nat. Rev. Mol. Cell Biol. 5, 959-970
6. Carr, D. W., Stofko-Hahn, R. E., Fraser, I. D., Bishop, S. M., Acott, T. S., Brennan, R. G., and Scott, J. D. (1991) Interaction of the regulatory subunit (RII) of cAMP-dependent protein kinase with RII-anchoring proteins occurs through an amphipathic helix binding motif J. Biol. Chem. 266, 14188-14192
7. Colledge, M. and Scott, J. D. (1999) AKAPs: from structure to function Trends Cell Biol. 9, 216-221
8. Newlon, M. G., Roy, M., Morikis, D., Hausken, Z. E., Coghlan, V., Scott, J. D., and Jennings, P. A. (1999) The molecular basis for protein kinase A anchoring revealed by solution NMR Nat. Struct. Biol. 6, 222-227
9. Newlon, M. G., Roy, M., Morikis, D., Carr, D. W., Westphal, R., Scott, J. D., and Jennings, P. A. (2001) A novel mechanism of PKA anchoring revealed by solution structures of anchoring complexes EMBO J. 20, 1651-1662
10. Rossi, E. A., Goldenberg, D. M., Cardillo, T. M., Stein, R., and Chang, C. H. (2009) Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma Blood 113, 6161-6171
11. Gupta, P., Goldenberg, D. M., Rossi, E. A., and Chang, C. H. (2010) Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias Blood 116, 3258-3267
12. Rossi, E. A., Goldenberg, D. M., Cardillo, T. M., Stein, R., and Chang, C. H. (2009) CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas Blood 114, 3864-3871
13. Rossi, E. A., Rossi, D. L., Stein, R., Goldenberg, D. M., and Chang, C. H. (2010) A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells Cancer Res. 70, 7600-7609
14. Rossi, E. A., Rossi, D. L., Cardillo, T. M., Stein, R., Goldenberg, D. M., and Chang, C. H. (2011) Preclinical studies on targeted delivery of multiple IFN{alpha}2b to HLA-DR in diverse hematologic cancers Blood 118, 1877-1884
15. Rossi, D. L., Rossi, E. A., Goldenberg, D. M., and Chang, C. H. (2011) A new mammalian host cell with enhanced survival enables completely serum-free development of high-level protein production cell lines Biotechnol. Prog. 27, 766-775
16. Chang, C. H., Rossi, E. A., Cardillo, T. M., Nordstrom, D. L., McBride, W. J., and Goldenberg, D. M. (2009) A new method to produce monoPEGylated dimeric cytokines shown with human interferon-alpha2b Bioconjugate Chem. 20, 1899-1907
17. Rossi, E. A., Goldenberg, D. M., Cardillo, T. M., Stein, R., Wang, Y., and Chang, C. H. (2008) Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics Cancer Res. 68, 8384-8392
18. Wang, W., Lu, P., Fang, Y., Hamuro, L., Pittman, T., Carr, B., Hochman, J., and Prueksaritanont, T. (2011) Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences Drug Metab. Dispos. 39, 1469-1477
19. Feng, Y., Gong, R., and Dimitrov, D. S. (2011) Design, expression and characterization of a soluble single-chain functional human neonatal Fc receptor Protein Expr. Purif. 79, 66-71
20. Kontermann, R. E. (2012) Antibody-cytokine fusion proteins Arch. Biochem. Biophys. 526, 194-205
21. Huber, A. H., Kelley, R. F., Gastinel, L. N., and Bjorkman, P. J. (1993) Crystallization and stoichiometry of binding of a complex between a rat intestinal Fc receptor and Fc J. Mol. Biol. 230, 1077-1083
22. Raghavan, M., Chen, M. Y., Gastinel, L. N., and Bjorkman, P. J. (1994) Investigation of the interaction between the class I MHC-related Fc receptor and its immunoglobulin G ligand Immunity 1, 303-315
23. Dall'Acqua, W. F., Woods, R. M., Ward, E. S., Palaszynski, S. R., Patel, N. K., Brewah, Y. A., Wu, H., Kiener, P. A., and Langermann, S. (2002) Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences J. Immunol. 169, 5171-5180
24. Gurbaxani, B., la Cruz, L. L., Chintalacharuvu, K., and Morrison, S. L. (2006) Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life Mol. Immunol. 43, 1462-1473
25. Suzuki, T., Ishii-Watabe, A., Tada, M., Kobayashi, T., Kanayasu-Toyoda, T., Kawanishi, T., and Yamaguchi, T. (2010) Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR J. Immunol. 184, 1968-1976
26. Lee, H., Kimko, H. C., Rogge, M., Wang, D., Nestorov, I., and Peck, C. C. (2003) Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis Clin. Pharmacol. Ther. 73, 348-365
27. Peng, L. S., Penichet, M. L., and Morrison, S. L. (1999) A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity J. Immunol. 163, 250-258
28. Dela Cruz, J. S., Trinh, K. R., Morrison, S. L., and Penichet, M. L. (2000) Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity J. Immunol. 165, 5112-5121
29. Dong, J., Sereno, A., Aivazian, D., Langley, E., Miller, B. R., Snyder, W. B., Chan, E., Cantele, M., Morena, R., Joseph, I. B., Boccia, A., Virata, C., Gamez, J., Yco, G., Favis, M., Wu, X., Graff, C. P., Wang, Q., Rohde, E., Rennard, R., Berquist, L., Huang, F., Zhang, Y., Gao, S. X., Ho, S. N., Demarest, S. J., Reff, M. E., Hariharan, K., and Glaser, S. M. (2011) A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity MAbs 3, 273-288
30. Croasdale, R., Wartha, K., Schanzer, J. M., Kuenkele, K. P., Ries, C., Mayer, K., Gassner, C., Wagner, M., Dimoudis, N., Herter, S., Jaeger, C., Ferrara, C., Hoffmann, E., Kling, L., Lau, W., Staack, R. F., Heinrich, J., Scheuer, W., Stracke, J., Gerdes, C., Brinkmann, U., Umana, P., and Klein, C. (2012) Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition Arch. Biochem. Biophys. 526, 206-218
31. Gillies, S. D., Reilly, E. B., Lo, K. M., and Reisfeld, R. A. (1992) Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells Proc. Natl. Acad. Sci. U. S. A. 89, 1428-1432